Thermo Fisher Scientific (TMO) announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients. The registry fills a significant gap for real-world evidence and adolescentspecific developmental and safety data related to novel therapies for AD, complementing the existing adult CorEvitas AD Registry launched in 2020. CorEvitas, acquired in August 2023, is part of Thermo Fi ...